基于长链非编码RNA的分类器识别FGFR3活性升高的更具侵袭性低级别Ta期膀胱癌
研究开发了一种单样本转录组分类器,用于在患者层面识别低级别Ta期非肌层浸润性膀胱癌中的侵袭性LC2亚群。该分类器在UROMOL队列(n=276)中训练测试,并在Hurst队列(n=72)中验证,LC2肿瘤表现为增殖增加、FGFR3通路活性升高及免疫活性降低。LC2状态与更差的无复发生存显著相关(HR 4.52, 95%CI 1.78-11.5; p=0.001)。
要点
- LC2分类器可在单样本水平识别侵袭性TaLG NMIBC,跨平台可重复。
- LC2肿瘤增殖增加、FGFR3通路活性升高、免疫活性降低。
- LC2状态与复发风险显著升高相关(HR 4.52)。
核心结论
- 开发出单样本转录组分类器识别侵袭性TaLG NMIBC,跨平台可重复。
- 若经验证,该模型有望支持临床决策。
研究设计与样本
- 使用UROMOL队列(n=276)进行训练和测试,Hurst队列(n=72)进行验证。
- 通过中位绝对偏差和嵌套交叉验证进行特征选择,采用弹性网络回归模型(α=0.5)进行十折交叉验证训练。
主要发现
- LC2肿瘤表现出更高的增殖(G2M/E2F特征)、升高的FGFR3通路活性以及降低的sonic hedgehog信号和免疫活性(p < 0.001)。
- 分类器在Hurst队列中识别出7/72个LC2肿瘤。
- LC2-TaLG患者无复发生存显著更差(log-rank p < 0.001)。
- 单变量Cox回归分析显示LC2状态与复发强烈相关(风险比4.52,95%置信区间1.78-11.5;p = 0.001)。
- Hurst队列中LC2预测的肿瘤显示出相似的生物学模式。
关键数值与推荐
- LC2状态与复发风险比4.52(95%CI 1.78-11.5;p=0.001)。
- LC2肿瘤增殖、FGFR3通路活性及免疫活性差异p < 0.001。
临床怎么用
- 该分类器可用于识别低级别Ta期NMIBC中更具侵袭性的亚群,辅助临床决策。
局限性
- 需进一步验证后方可用于临床决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Low-grade, stage Ta (TaLG) non-muscle-invasive bladder cancer (NMIBC) is generally nonaggressive; yet, some patients experience recurrence or progression. We previously identified long noncoding RNA cluster 2 (LC2) as an aggressive TaLG subgroup via consensus clustering, which required a cohort-level analysis. We developed a single-sample transcriptome classifier for patient-level LC2 identification. METHODS: Using the UROMOL cohort (n = 276) for training/testing and the Hurst (Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight. Cell Rep Med 2021;2:100472) cohort (n = 72) for validation, we performed feature selection via median absolute deviation and nested cross-validation. An elastic net regression model (α = 0.5) was trained using ten-fold cross-validation. Performance was evaluated through a pathway analysis, with prognostic significance assessed by Kaplan-Meier and univariable Cox regression. KEY FINDINGS AND LIMITATIONS: Biological characterization revealed that LC2 tumors exhibited higher proliferation (G2M/E2F signatures), elevated FGFR3 pathway activity, and reduced sonic hedgehog signaling and immune activity (p < 0.001). The classifier identified 7/72 LC2 tumors in the Hurst cohort. LC2-TaLG patients had significantly worse recurrence-free survival (log-rank p < 0.001). On univariable Cox regression analysis, LC2 status was strongly associated with recurrence (hazard ratio 4.52, 95% confidence interval 1.78-11.5; p = 0.001). LC2-predicted tumors in the Hurst cohort showed similar biological patterns. CONCLUSIONS AND CLINICAL IMPLICATIONS: We developed a single-sample transcriptomic classifier identifying aggressive TaLG NMIBC, demonstrating reproducibility across platforms. If validated, this model has the potential to support clinical decision-making.
引用
- Thu Phung TA, Weng R, Black PC, et al. A Long Noncoding RNA-based Classifier for Identifying More Aggressive Low-grade Ta Bladder Cancer with Elevated FGFR3 Activity. Eur Urol Oncol. 2026. PMID: 41763905. doi:10.1016/j.euo.2026.02.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。